

## **REMARKS**

All the claims submitted for examination in this application have been objected to or rejected. Applicants have amended their claims and respectfully submit that all the claims currently in this application are patentable over the objection and rejections of record.

Of the nine claims examined on the merits in this application seven of them, Claims 12-18, have been rejected on formal and substantive grounds. Applicants have cancelled Claims 12-18.

The two remaining claims, Claims 19 and 20, stand objected to as being dependent upon a rejected base claim. However, the Official Action indicates that if those claims were rewritten in independent form and included all the limitations of the base claim and any intervening claims, those claims would be allowable.


Claims 19 and 20, the two claims subject to objection, have been amended so that they are in independent form. It is emphasized that their dependency from original independent Claim 12 is irrelevant insofar as Claims 19 and 20 are directed to specific compounds within the contemplation of structural formula (I) of Claim 12. The inclusion of formula (I) is unnecessary in that the members of the Markush groups of Claims 19 and 20 do not require that formula for those skilled in the art to appreciate the scope of invention embodied by those Markush group members. Therefore, applicants submit that amended independent Claims 19 and 20 are in condition for allowance.

In view of the amendment to the claims, the title has been amended to recognize that the claims of the present application are limited to hydroxyphenyl-pyrazole derivatives active as kinase inhibitors. That is, the title has been amended to remove the inclusion of any other subject matter.

The instant Amendment is restricted to the amendment of the claims to expedite allowance in view of the outstanding Official Action. As such, this amendment places the present application in condition for allowance. Admission of this amendment, after final rejection, is therefore deemed appropriate. Such action is respectfully urged.

The above amendment and remarks establish the patentable nature of all the claims currently in this application. Notice of Allowance and passage to issue of these claims, Claims 19 and 20, is therefore respectfully solicited.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'Peter I. Bernstein', with a long horizontal flourish extending to the right.

Peter I. Bernstein  
Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343  
PIB/MB:dg